4 results
PrimaryObjectives: 1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C. 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetrapib 100 mg.Hypotheses: 1.…
Part 1 -Blinded Treatment Period: Primary Objective:To evaluate the efficacy of inhaled nitric oxide (iNO) on exercise using 6-minute walk distance (6MWD) in subjects with pulmonary arterial hypertension (PAH) currently receiving background PAH…
- To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of radiographic progression-free survival PFS) in patients with PTEN-deficient mHSPC.
The study will compare the effect of monalizumab and cetuximab (Arm A) relative to placebo and cetuximab (Arm B) by assessment of Overall Survival in HPV-unrelated participants. The formal statistical analysis will be performed to test the following…